-
Mashup Score: 18Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics - 7 day(s) ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaborat…
Source: www.businesswire.comCategories: General Medicine NewsTweet
-
Mashup Score: 3
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Respo…
Source: www.businesswire.comCategories: General Medicine NewsTweet-
https://t.co/jPQeDkIeLl. Looks like Glofi-GemOX is a no go from the FDA standpoint. @JulioChavezMD @lymphomaphilia @JuanAlderuccio @bshah @iHematologo @GuiperiniMD @KrishPatelMD. Was there any hope left s/p ODAC?
-
-
Mashup Score: 27Stephenson Global Scholar Grants Program Awards $5.3 Million to Drive Breakthroughs in Pancreatic Cancer Research - 14 day(s) ago
The Stephenson Global Pancreatic Cancer Research Institute and its partner City of Hope, one of the country’s largest and most advanced cancer research and t…
Source: www.businesswire.comCategories: General Medicine NewsTweet-
Congratulations to all the teams selected for the Stephenson Global Scholar Grants in #PancreaticCancer research. @mvh_lab @LyssiotisLab @LabJacks and other awardees! https://t.co/HF89FMIPz1
-
-
Mashup Score: 10
Lyra Health, the leading provider of mental health benefits for employers, has acquired Bend Health Inc., a leader in pediatric mental health care, to better…
Source: www.businesswire.comCategories: General Medicine News, Future of MedicineTweet-
Major behavioral health news is out. Lyra just acquired Bend Health, undoubtedly to move more deeply into pediatrics! https://t.co/zfsZOtrG2N
-
-
Mashup Score: 10
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from the …
Source: www.businesswire.comCategories: General Medicine NewsTweet-
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence - https://t.co/8fAI98yReI
-
-
Mashup Score: 0
DESKi, a healthtech company developing AI-powered diagnostic tools in collaboration with clinicians and researchers, today announced the close of a $6 millio…
Source: www.businesswire.comCategories: General Medicine NewsTweet-
DESKi Closes $6M Seed Round to Bring #AI-Powered Heart Scans to Market: Funding follows #FDA clearance and landmark trial validating novice-led #cardiac imaging | #radiology https://t.co/XoDSdXN8ce
-
-
Mashup Score: 0
SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice artificial intelligence, today announced its partnership with Allina Health and deployment of “A…
Source: www.businesswire.comCategories: General Medicine NewsTweet-
.@SoundHound and @AllinaHealth Launch #AI Agent to Redefine #PatientEngagement | #agenticAI https://t.co/xeNKsxpFo1
-
-
Mashup Score: 0Claritev Joins Coalition for Health AI to Advance Responsible Innovation in Healthcare Technology - 1 month(s) ago
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more afford…
Source: www.businesswire.comCategories: General Medicine NewsTweet-
.@Claritev Joins Coalition for Health AI @CHAI_nonprofit to Advance Responsible #Innovation in #Healthcare Technology | #AI https://t.co/cCgzsXv79N
-
-
Mashup Score: 0Autonomize AI Raises $28 Million Series A to Power Next-Generation Agentic AI for Healthcare and Life Sciences - 1 month(s) ago
Autonomize AI, a pioneer in AI-driven healthcare solutions, today announced that it raised $28 million in Series A funding, bringing total capital raised to …
Source: www.businesswire.comCategories: General Medicine NewsTweet-
.@AutonomizeAI Raises $28M Series A to Power Next-Gen #AgenticAI for #Healthcare & Life Sciences; use cases include care management, utilization management, and benefits checks to chart reviews https://t.co/OBbavkBNFW
-
-
Mashup Score: 33
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty can…
Source: www.businesswire.comCategories: General Medicine NewsTweet-
FDA approves UGN-102, mitomycin intravesical solution (ZUSDURI™ ) for Recurrent Low-Grade IR NMIBC https://t.co/GbjGQhgu68 @UroGenPharma @UrogerliMD @siadaneshmand @MaxKates @IBCG_BladderCA @joanfundi https://t.co/59bd7MX66q
-
The people at Arrowhead would like you to know that if $SRPT is facing an extinction level event they are well positioned to skip right around the crater. Thank you. That is all for now. https://t.co/EHDofxI1Gj